SecBot SecBot
8-K ·Filed Nov 12, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4d 16h ago SEC0001193125-26-456888
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

The settlement removes litigation overhang and secures LYBALVI exclusivity until at least late 2039. Monitor FTC/DOJ review and any potential earlier entry triggers. No immediate revenue impact, but the clarity on generic entry timing supports long-term revenue visibility for LYBALVI.

DirectionNeutral
Confidencehigh
Horizonweeks

LYBALVI

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercially available (FDA approved May 28, 2021). A pediatric label expansion, if supported by the ENLIGHTEN-Youth trial, would be a supplemental approval, typically 6-12 months after data submission.
Next catalyst
None dated

What to watchWatch for topline results from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results unreported as of Nov 4). Positive data could support a label expansion into adolescents, opening a new patient segment. Separately, LYBALVI's expanded payer access (~80% of covered lives) should drive prescription volume growth into 2027, though gross-to-net adjustments are expected to rise to ~45%.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$46.98
T+0 close · Nov 12, 2026 · via day close
Latest settled
+0.11%
T+1 · $47.03
Vs SPY
+0.47%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $46.98entry
  2. T+1 · 4d ago +0.11%α +0.47% · $47.03
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alkermes settled a patent infringement lawsuit with Teva over LYBALVI (olanzapine/samidorphan). Teva will receive a license to launch a generic version no earlier than November 12, 2039 (or May 12, 2040 if pediatric exclusivity is obtained), resolving the ANDA litigation. The settlement removes near-term generic risk but defers the revenue impact by over a decade.

Key Facts

  • Alkermes and Teva entered a Confidential Settlement and License Agreement on November 6, 2026, resolving patent litigation over LYBALVI.
  • Teva will receive a non-exclusive, royalty-free license to market its generic version of LYBALVI beginning November 12, 2039, or May 12, 2040 if pediatric exclusivity is granted.
  • The lawsuit was filed by Alkermes against Teva in the U.S. District Court for the District of New Jersey regarding Teva's ANDA No. 220379.
  • The parties filed a joint Stipulation of Dismissal with Prejudice on November 9, 2026.
  • The settlement is subject to review by the U.S. FTC and DOJ.

Financial Impact

No financial terms disclosed; the license is royalty-free. The settlement pushes generic entry to late 2039/2040, preserving LYBALVI exclusivity for approximately 13 years from the filing date.

revenue

Risk Factors

  • FTC or DOJ review could challenge or modify the settlement terms.
  • Earlier generic entry is possible under certain circumstances not detailed in the filing.
  • LYBALVI revenue concentration risk remains if the product is a significant portion of Alkermes' total revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-456888
Document: 0001193125-26-456888-index-headers.html0001193125-26-456888
Document: 0001193125-26-456888-index.html0001193125-26-456888
Document: 0001193125-26-456888.txt0001193125-26-456888

Track record

23 reports on ALKS

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $46.98 Now $46.53 −0.96% settles Feb 10
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
  3. Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
  4. Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
  5. Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
  6. Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
  7. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
  8. Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
  9. Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
  10. Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026